Britain’s regulator approves a dose of up to 7.2 mg of semaglutide per week, up from 2.4 mg.

By Bhanvi Satija and Maggie Fick LONDON, Jan 16 (Reuters) - Novo Nordisk's Wegovy weight-loss pill has made an encouraging ...

Jan 9 (Reuters) - Amazon Pharmacy said on Friday it now offers Novo Nordisk's Wegovy weight-loss pill through insurance plans as well as through a cash-pay option. Eligible customers with commercial ...

Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, ...

Novo Nordisk executive Dave Moore touted high interest in Wegovy's oral version of its injectable GLP-1 weight-loss ...

Novo Nordisk announced Jan. 5 it will begin offering its Wegovy weight loss pill to self-paying patients in the United States, expanding access to the popular GLP-1 medication beyond injections.

Both companies now aim to win in the oral weight loss drug market.

The U.K.’s health regulator approved a higher dose of Novo Nordisk’s Wegovy weight-loss drug applicable to patients with a ...

The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.

Two weeks after securing approval from the U.S. Food and Drug Administration, a once-daily pill version of Novo Nordisk‘s popular GLP-1 weight loss drug Wegovy officially hit the market. In a Jan. 5 ...

The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss ...

Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven ...